Empowered Funds
KLRS icon

Empowered Funds’s Kalaris Therapeutics KLRS Stock Holding History

Empowered Funds’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$65K Buy
+22,500
New +$87K ﹤0.01% 2456

Other funds holding KLRS

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
WT
WHI Trust Chicago, Illinois $177M AUM 7.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Empowered Funds's KLRS Position: Q3 2026 in Review

Empowered Funds opened a new position in Kalaris Therapeutics (KLRS) in Q3 2026: 22,500 shares worth $65K. The stake represents ﹤0.01% of the portfolio and ranks #2456 among its holdings.

37 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Empowered Funds held 22,500 shares of Kalaris Therapeutics worth $65K as of Q3 2026.
  • Kalaris Therapeutics was a new Empowered Funds position in Q3 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2456 holding.
  • 37 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.